Table 4.
Prognostic factors on overall survival and progression-free survival by Cox proportional-hazards model
| Overall survival | Progression-free survival | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| Variables | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value |
| Age (<50 vs. ≥50) | 1.21 (0.59-2.51) | 0.61 | 1.24 (0.69-2.21) | 0.47 | ||||
| ECOG PS (0 vs. 1 or 2) | 0.45 (0.22-0.95) | 0.04 | 0.53 (0.25-1.12) | 0.1 | 0.48 (0.27-0.87) | 0.02 | 0.57 (0.31-1.03) | 0.06 |
| Tumor shape (exophytic vs. infiltrative) | 1.75 (0.85-3.64) | 0.13 | 1.75 (0.98-3.14) | 0.06 | 1.67 (0.93-2.99) | 0.09 | ||
| Tumor size (<5 vs. ≥5 cm) | 0.67 (0.3-1.47) | 0.31 | 0.72 (0.39-1.33) | 0.29 | ||||
| Parametrial involvement (no vs. yes) | 0.4 (0.1-1.7) | 0.22 | 0.5 (0.18-1.39) | 0.18 | ||||
| Endocervical extension (others vs. yes) | 1.85 (0.82-4.17) | 0.14 | 1.47 (0.8-2.7) | 0.22 | ||||
| Pelvic nodal involvement (no vs. yes) | 0.78 (0.32-1.91) | 0.58 | 0.71 (0.34-1.47) | 0.35 | ||||
| Hydronephrosis (no vs. yes) | 1.21 (0.42-3.5) | 0.72 | 0.82 (0.4-1.65) | 0.57 | ||||
| Stage (IB vs. IIB vs. IIIA-IVA) | Referent 0.38 (0.09-1.7) | 0.45 | Referent 0.45 (0.15-1.3) | 0.32 | ||||
| 0.9 (0.42-1.92) | 0.81 (0.44-1.49) | |||||||
| Radiotherapy duration (<10 vs. ≥10 weeks) | 0.59 (0.28-1.23) | 0.16 | 0.62 (0.35-1.12) | 0.11 | ||||
| Doses to point A (<75 vs. ≥75 Gy) | 0.87 (0.42-1.8) | 0.71 | 0.64 (0.36-1.15) | 0.14 | ||||
| Doses to PAN (<50.4 vs. ≥50.4 Gy) | 1.09 (0.46-2.55) | 0.85 | 0.75 (0.35-1.6) | 0.45 | ||||
| Treatment period (<2000 vs. ≥2000) | 1.25 (0.59-2.65) | 0.56 | 0.98 (0.54-1.76) | 0.95 | ||||
| Treatment response (CR vs. PR) | 0.36 (0.16-0.81) | 0.01 | 0.43 (0.19-0.98) | 0.04 | 0.27 (0.14-0.51) | <0.001 | 0.3 (0.16-0.58) | <0.001 |
| Concurrent chemotherapy (no vs. yes) | 1.23 (0.59-2.54) | 0.59 | 0.88 (0.49-1.57) | 0.65 | ||||
Abbreviation: ECOG PS Eastern Cooperative Oncology Group performance status, CR complete remission, PR partial response, HR hazard ratio, CI confidence interval.